Lu Hongsheng, Cao Xuequan, Chen Qi, Chen Lanxi, Chen Lili, Gan Meifu
Department of Pathology, Taizhou Central Hospital, Taizhou, Zhejiang, 318000, China.
Anat Rec (Hoboken). 2015 Apr;298(4):727-34. doi: 10.1002/ar.23093. Epub 2014 Dec 9.
To explore the relationship between Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 3(MEKK3) and cell apoptosis, clinicopathology, and prognosis, we characterize the expression of MEKK3, survivin and stat3 in renal clear cell carcinoma (RCCC). The expressions were measured by RT-PCR and Western blot from 15 cases of RCCC and 15 cases of control group (CG). Protein expression was detected by tissue microarray and immunochemistry in 98 cases of RCCC, 28 cases of CG. Expression patterns were analyzed for their association with pathological factors, correlation and prognosis in RCCC. Expression of MEKK3, survivin and stat3 mRNA was significantly higher in RCCC than in CG (P < 0.01). MEKK3, survivin and stat3 expression differed significantly between pathological grade (P < 0.05) and clinical stage (P < 0.05). MEKK3 expression was positively correlated with survivin and stat3 (P < 0.01). Furthermore, we investigated the role of MEKK3 in RCCC using the technique of RNA silencing via small interfering (siRNA) in ACHN cells. The results indicated that the targeted depletion of MEKK3 caused a dramatic massive apoptotic cell death. Kaplan-Meier survival analysis showed that MEKK3 and survivin expression, pathological grade, and clinical stage reduced cumulative survival. Cox multivariate regression analysis showed that MEKK3, survivin, and clinical staging were independent prognostic factors in renal cancer (P < 0.05). MEKK3 can be used as an important marker of prognostic evaluation in RCCC. The mechanism may be closely related to cell apoptosis. Targeted therapy of MEKK3 may provide a new strategy for treatment of chemotherapeutic-resistant tumors.
为探讨丝裂原活化蛋白激酶/细胞外信号调节激酶激酶激酶3(MEKK3)与细胞凋亡、临床病理及预后之间的关系,我们对肾透明细胞癌(RCCC)中MEKK3、生存素和信号转导与转录激活因子3(STAT3)的表达进行了特征分析。通过逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹法检测了15例RCCC患者及15例对照组(CG)患者的上述指标表达情况。采用组织芯片和免疫组化法检测了98例RCCC患者及28例CG患者的蛋白质表达情况。分析了RCCC中上述指标的表达模式与病理因素、相关性及预后的关系。RCCC中MEKK3、生存素和STAT3 mRNA的表达显著高于CG组(P<0.01)。MEKK3、生存素和STAT3的表达在病理分级(P<0.05)和临床分期(P<0.05)之间存在显著差异。MEKK3的表达与生存素和STAT3呈正相关(P<0.01)。此外,我们通过小干扰RNA(siRNA)介导的RNA沉默技术研究了MEKK3在ACHN细胞中的作用。结果表明,靶向敲低MEKK3可导致大量细胞发生显著的凋亡性死亡。Kaplan-Meier生存分析显示,MEKK3和生存素的表达、病理分级及临床分期降低了累积生存率。Cox多因素回归分析显示,MEKK3、生存素和临床分期是肾癌的独立预后因素(P<0.05)。MEKK3可作为RCCC预后评估的重要标志物。其机制可能与细胞凋亡密切相关。MEKK3的靶向治疗可能为化疗耐药肿瘤的治疗提供新策略。